|
Oct 8
|
Registrational Phase III Studies of APG-2449 Cleared by China CDE for the Treatment of Patients with NSCLC
|
|
Jun 24
|
Ascentage Pharma Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering of American Depositary Shares
|
|
Jun 21
|
Ascentage Pharma Announces Closing of US$75 Million Equity Investment by Takeda
|
|
Jun 18
|
Live from EHA 2024 | Ascentage Pharma Releases Updated Data of Lisaftoclax in Patients with R/R MM and AL Amyloidosis Highlighting Marked Improvement in ORR
|
|
Jun 18
|
Live from EHA 2024 | Posters Featuring Results from Three Studies of Olverembatinib, Including Encouraging Data from US Study in CML and Ph+ ALL
|
|
Apr 7
|
AACR 2024 | Ascentage Pharma Presents Results from Three Studies at 2024 American Association of Cancer Research Annual Meeting
|
|
Feb 14
|
Global Registrational Phase III Study of Olverembatinib (HQP1351) Cleared by FDA
|
|
Jan 17
|
Olverembatinib Included in Newest Guidelines on Chronic Myeloid Leukemia (CML) Management from the National Comprehensive Cancer Network (NCCN)
|
|
Jan 11
|
Ascentage Pharma Presented at 42nd Annual J.P. Morgan Healthcare Conference
|
|
Jan 2
|
Ascentage Pharma to Present at 42nd J.P. Morgan Healthcare Conference
|
|
Aug 21
|
Ascentage Pharma Announces 2023 Interim Results Highlighting Significant Increase in Sales and Clearance for Global Registrational Phase III Trial
|